Alendronate and risk of lower limb ischemic vascular events: A population-based cohort study

C. K. Chen, H. T. Chang, H. P. Chou, M. H. Lee, Y. C. Chen, Y. C. Huang, T. J. Chen, H. L. Chang, C. C. Shih

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Summary: While alendronate inhibits atherosclerosis experimentally, its effect on lower limb ischemia risk is unknown. Our results suggest that alendronate reduces the risk of lower limb ischemic vascular events requiring surgical interventions, including amputation. Our results are relevant for patients at risk of lower limb ischemia undergoing fragility fracture treatment. Introduction: This study aimed to determine the association between alendronate therapy and the risk of lower limb ischemic vascular events (i.e., bypass surgery, endovascular stenting, and major lower limb amputation for lower limb ischemia). Methods: We used a nationwide population-based cohort of patients aged over 50 years diagnosed with a vertebral or hip fracture between January 1999 and June 2010. We compared the risk of lower limb ischemic vascular events between patients undergoing treatment with alendronate (n =3,731) and an age- and sex-matched comparison group (n =7,462) over 5 years of follow-up. Hazard ratios (HR) were estimated using Cox proportional regression analysis with adjustment for treatment status, comorbidities, and other variables. Results: Ten patients (0.3%) in the alendronate treatment group had a lower limb ischemic vascular event compared with 51 patients (0.7%) in the comparison group. The incidence of lower limb ischemic vascular events was 8.4 (95% CI, 4.0-15.5) per 10,000 person-years in the alendronate group and 21.8 (95% CI, 16.2-28.7) per 10,000 person-years in the comparison group. The risk of a lower limb ischemic vascular event in the alendronate treatment group was lower (adjusted HR, 0.41; 95% CI, 0.21-0.82). Conclusion: Alendronate treatment was associated with a reduced risk of lower limb ischemic vascular events among hip or vertebral fragility fracture patients.

Original languageEnglish
Pages (from-to)673-680
Number of pages8
JournalOsteoporosis International
Volume25
Issue number2
DOIs
Publication statusPublished - Jan 1 2014
Externally publishedYes

Fingerprint

Alendronate
Blood Vessels
Lower Extremity
Cohort Studies
Population
Ischemia
Amputation
Therapeutics
Hip Fractures
Comorbidity
Hip
Atherosclerosis
Research Design
Regression Analysis

Keywords

  • Alendronate
  • Bisphosphonates
  • Intervention
  • Lower limb ischemia
  • Osteoporosis
  • Peripheral vascular disease

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Alendronate and risk of lower limb ischemic vascular events : A population-based cohort study. / Chen, C. K.; Chang, H. T.; Chou, H. P.; Lee, M. H.; Chen, Y. C.; Huang, Y. C.; Chen, T. J.; Chang, H. L.; Shih, C. C.

In: Osteoporosis International, Vol. 25, No. 2, 01.01.2014, p. 673-680.

Research output: Contribution to journalArticle

Chen, CK, Chang, HT, Chou, HP, Lee, MH, Chen, YC, Huang, YC, Chen, TJ, Chang, HL & Shih, CC 2014, 'Alendronate and risk of lower limb ischemic vascular events: A population-based cohort study', Osteoporosis International, vol. 25, no. 2, pp. 673-680. https://doi.org/10.1007/s00198-013-2478-3
Chen, C. K. ; Chang, H. T. ; Chou, H. P. ; Lee, M. H. ; Chen, Y. C. ; Huang, Y. C. ; Chen, T. J. ; Chang, H. L. ; Shih, C. C. / Alendronate and risk of lower limb ischemic vascular events : A population-based cohort study. In: Osteoporosis International. 2014 ; Vol. 25, No. 2. pp. 673-680.
@article{3fce080eeed640e1a132358556f9789d,
title = "Alendronate and risk of lower limb ischemic vascular events: A population-based cohort study",
abstract = "Summary: While alendronate inhibits atherosclerosis experimentally, its effect on lower limb ischemia risk is unknown. Our results suggest that alendronate reduces the risk of lower limb ischemic vascular events requiring surgical interventions, including amputation. Our results are relevant for patients at risk of lower limb ischemia undergoing fragility fracture treatment. Introduction: This study aimed to determine the association between alendronate therapy and the risk of lower limb ischemic vascular events (i.e., bypass surgery, endovascular stenting, and major lower limb amputation for lower limb ischemia). Methods: We used a nationwide population-based cohort of patients aged over 50 years diagnosed with a vertebral or hip fracture between January 1999 and June 2010. We compared the risk of lower limb ischemic vascular events between patients undergoing treatment with alendronate (n =3,731) and an age- and sex-matched comparison group (n =7,462) over 5 years of follow-up. Hazard ratios (HR) were estimated using Cox proportional regression analysis with adjustment for treatment status, comorbidities, and other variables. Results: Ten patients (0.3{\%}) in the alendronate treatment group had a lower limb ischemic vascular event compared with 51 patients (0.7{\%}) in the comparison group. The incidence of lower limb ischemic vascular events was 8.4 (95{\%} CI, 4.0-15.5) per 10,000 person-years in the alendronate group and 21.8 (95{\%} CI, 16.2-28.7) per 10,000 person-years in the comparison group. The risk of a lower limb ischemic vascular event in the alendronate treatment group was lower (adjusted HR, 0.41; 95{\%} CI, 0.21-0.82). Conclusion: Alendronate treatment was associated with a reduced risk of lower limb ischemic vascular events among hip or vertebral fragility fracture patients.",
keywords = "Alendronate, Bisphosphonates, Intervention, Lower limb ischemia, Osteoporosis, Peripheral vascular disease",
author = "Chen, {C. K.} and Chang, {H. T.} and Chou, {H. P.} and Lee, {M. H.} and Chen, {Y. C.} and Huang, {Y. C.} and Chen, {T. J.} and Chang, {H. L.} and Shih, {C. C.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00198-013-2478-3",
language = "English",
volume = "25",
pages = "673--680",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "2",

}

TY - JOUR

T1 - Alendronate and risk of lower limb ischemic vascular events

T2 - A population-based cohort study

AU - Chen, C. K.

AU - Chang, H. T.

AU - Chou, H. P.

AU - Lee, M. H.

AU - Chen, Y. C.

AU - Huang, Y. C.

AU - Chen, T. J.

AU - Chang, H. L.

AU - Shih, C. C.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Summary: While alendronate inhibits atherosclerosis experimentally, its effect on lower limb ischemia risk is unknown. Our results suggest that alendronate reduces the risk of lower limb ischemic vascular events requiring surgical interventions, including amputation. Our results are relevant for patients at risk of lower limb ischemia undergoing fragility fracture treatment. Introduction: This study aimed to determine the association between alendronate therapy and the risk of lower limb ischemic vascular events (i.e., bypass surgery, endovascular stenting, and major lower limb amputation for lower limb ischemia). Methods: We used a nationwide population-based cohort of patients aged over 50 years diagnosed with a vertebral or hip fracture between January 1999 and June 2010. We compared the risk of lower limb ischemic vascular events between patients undergoing treatment with alendronate (n =3,731) and an age- and sex-matched comparison group (n =7,462) over 5 years of follow-up. Hazard ratios (HR) were estimated using Cox proportional regression analysis with adjustment for treatment status, comorbidities, and other variables. Results: Ten patients (0.3%) in the alendronate treatment group had a lower limb ischemic vascular event compared with 51 patients (0.7%) in the comparison group. The incidence of lower limb ischemic vascular events was 8.4 (95% CI, 4.0-15.5) per 10,000 person-years in the alendronate group and 21.8 (95% CI, 16.2-28.7) per 10,000 person-years in the comparison group. The risk of a lower limb ischemic vascular event in the alendronate treatment group was lower (adjusted HR, 0.41; 95% CI, 0.21-0.82). Conclusion: Alendronate treatment was associated with a reduced risk of lower limb ischemic vascular events among hip or vertebral fragility fracture patients.

AB - Summary: While alendronate inhibits atherosclerosis experimentally, its effect on lower limb ischemia risk is unknown. Our results suggest that alendronate reduces the risk of lower limb ischemic vascular events requiring surgical interventions, including amputation. Our results are relevant for patients at risk of lower limb ischemia undergoing fragility fracture treatment. Introduction: This study aimed to determine the association between alendronate therapy and the risk of lower limb ischemic vascular events (i.e., bypass surgery, endovascular stenting, and major lower limb amputation for lower limb ischemia). Methods: We used a nationwide population-based cohort of patients aged over 50 years diagnosed with a vertebral or hip fracture between January 1999 and June 2010. We compared the risk of lower limb ischemic vascular events between patients undergoing treatment with alendronate (n =3,731) and an age- and sex-matched comparison group (n =7,462) over 5 years of follow-up. Hazard ratios (HR) were estimated using Cox proportional regression analysis with adjustment for treatment status, comorbidities, and other variables. Results: Ten patients (0.3%) in the alendronate treatment group had a lower limb ischemic vascular event compared with 51 patients (0.7%) in the comparison group. The incidence of lower limb ischemic vascular events was 8.4 (95% CI, 4.0-15.5) per 10,000 person-years in the alendronate group and 21.8 (95% CI, 16.2-28.7) per 10,000 person-years in the comparison group. The risk of a lower limb ischemic vascular event in the alendronate treatment group was lower (adjusted HR, 0.41; 95% CI, 0.21-0.82). Conclusion: Alendronate treatment was associated with a reduced risk of lower limb ischemic vascular events among hip or vertebral fragility fracture patients.

KW - Alendronate

KW - Bisphosphonates

KW - Intervention

KW - Lower limb ischemia

KW - Osteoporosis

KW - Peripheral vascular disease

UR - http://www.scopus.com/inward/record.url?scp=84899123428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899123428&partnerID=8YFLogxK

U2 - 10.1007/s00198-013-2478-3

DO - 10.1007/s00198-013-2478-3

M3 - Article

C2 - 23943167

AN - SCOPUS:84899123428

VL - 25

SP - 673

EP - 680

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 2

ER -